Positive Data For Amgen/UCB's Romosozumab In Men With Osteoporosis
This article was originally published in Scrip
Executive Summary
Amgen and UCB have demonstrated the efficacy of their osteoporosis treatment romosozumab in men in the Phase III BRIDGE study. This follows Phase III FRAME data in women which will form the basis of a US filing later this year.
You may also be interested in...
Amgen Files Osteoporosis Drug In US Ahead Of Rival Merck
Amgen Inc. and partner UCB Group have filed their osteoporosis drug romosozumab, which is anticipated to drive sales of more than $700m worldwide by 2023, in the US for the treatment of postmenopausal women at risk of fractures.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.